Compare WK & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WK | IOVA |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 1.7B |
| IPO Year | 2014 | 2008 |
| Metric | WK | IOVA |
|---|---|---|
| Price | $74.29 | $8.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $95.30 | $9.00 |
| AVG Volume (30 Days) | 705.2K | ★ 14.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.53 | 14.84 |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $884,568,000.00 | N/A |
| Revenue This Year | $20.85 | $47.74 |
| Revenue Next Year | $15.43 | $40.31 |
| P/E Ratio | $131.98 | ★ N/A |
| Revenue Growth | ★ 19.75 | N/A |
| 52 Week Low | $43.34 | $1.76 |
| 52 Week High | $97.10 | $9.36 |
| Indicator | WK | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 68.07 |
| Support Level | $50.58 | $3.57 |
| Resistance Level | $80.56 | $9.36 |
| Average True Range (ATR) | 2.78 | 0.56 |
| MACD | -0.67 | -0.03 |
| Stochastic Oscillator | 44.44 | 69.82 |
Workiva Inc is an AI-powered platform for trust, transparency, and accountability. Accounting, finance, sustainability, risk, and audit teams rely on Workiva for their mission-critical work. It transforms how customers connect data, unify processes, and empower teams in a secure, AI-powered, audit-ready, collaborative platform. Company's Geographical region consist of USA, Netherland, UK, and Others. Majority of revenue is from USA.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.